CONUT评分在接受纳武利尤单抗治疗的晚期肾细胞癌患者中的预后意义
这项回顾性研究纳入60例酪氨酸激酶抑制剂治疗失败后接受纳武利尤单抗的IV期肾细胞癌患者,评估CONUT评分与无进展生存、癌症特异性生存及肿瘤缩小率的关系。CONUT评分≥5分与较差的无进展生存和癌症特异性生存独立相关,且与纳武利尤单抗最佳应答显著相关。
要点
- CONUT评分≥5分是晚期肾细胞癌接受纳武利尤单抗后不良无进展生存和癌症特异性生存的独立因素。
- CONUT评分与纳武利尤单抗的肿瘤缩小率显著相关,评分越高缩小率越差。
- 既往未行肾切除术同样与不良无进展生存和癌症特异性生存独立相关。
核心结论
- CONUT评分可能有助于预测接受纳武利尤单抗的晚期肾细胞癌患者的临床结局和治疗反应。
研究设计与样本
- 回顾性研究,纳入2016至2019年间在2个癌症中心接受纳武利尤单抗治疗的60例IV期肾细胞癌患者,均为既往酪氨酸激酶抑制剂治疗失败者。
主要发现
- 随访期间29例患者出现疾病进展,14例死于癌症。
- 无进展生存和癌症特异性生存均被CONUT评分0-1、2-4和≥5显著分层(p=0.002)。
- CONUT评分≥5分(对比0-1分)与不良无进展生存独立相关(HR 5.18,p=0.003),与不良癌症特异性生存独立相关(HR 15.34,p=0.014)。
- 既往未行肾切除术与不良无进展生存(HR 4.23,p=0.004)和癌症特异性生存(HR 6.57,p=0.001)独立相关。
- CONUT评分预测无进展生存和癌症特异性生存的C指数分别为0.694和0.737。
临床怎么用
- 对于酪氨酸激酶抑制剂治疗失败后拟接受纳武利尤单抗的晚期肾细胞癌患者,可计算CONUT评分以辅助预后评估和治疗决策。
局限性
- 回顾性研究,样本量较小(60例),仅来自2个癌症中心。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The controlling nutritional status (CONUT) score, consisting of albumin, lymphocytes and total cholesterol, is a validated, objective tool for nutritional assessment. Patients with advanced cancer frequently have malnutrition in association with cachexia and chronic inflammation. We explored the prognostic significance of the CONUT score in patients with advanced renal cell carcinoma receiving nivolumab. MATERIALS AND METHODS: This retrospective study included 60 patients with stage IV renal cell carcinoma treated with nivolumab after failure of prior tyrosine kinase inhibitors at 2 cancer centers between 2016 and 2019. Associations of the CONUT score with progression-free survival, cancer specific survival and tumor shrinkage rate were assessed. RESULTS: The median (range) CONUT score was 2 (0-10). During followup periods 29 and 14 patients exhibited disease progression and died of cancer, respectively. Both progression-free survival and cancer specific survival were significantly stratified by CONUT scores of 0 to 1, 2 to 4 and 5 or more (p=0.002). A CONUT score of 5 or more (versus score 0 to 1) was independently associated with unfavorable progression-free survival (HR 5.18, p=0.003) and cancer specific survival (HR 15.34, p=0.014), as was the absence of prior nephrectomy (HR 4.23, p=0.004 and HR 6.57, p=0.001, respectively). C-indices of the CONUT score for predicting progression-free survival and cancer specific survival were 0.694 and 0.737, respectively. The CONUT score was significantly associated with the best response to nivolumab with the median tumor shrinkage rate of -23%, +8% and +24% for CONUT scores of 0 to 1, 2 to 4 and 5 or more, respectively (p=0.021). CONCLUSIONS: The CONUT score may be useful to predict the clinical outcomes and therapeutic response in patients with advanced renal cell carcinoma receiving nivolumab.
引用
- Takemura K, Yuasa T, Fujiwara R, et al. Prognostic Significance of the Controlling Nutritional Status (CONUT) Score in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab after Failure of Prior Tyrosine Kinase Inhibitors. J Urol. 2020. PMID: 32567459. doi:10.1097/JU.0000000000001196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。